• Treatment of non-muscle invasive bladder cancer
  • The EAU approach to non-muscle invasive bladder cancer treatment
  • A single chemotherapy dose for low- or intermediate-risk patients
  • Further chemotherapy or long-term BCG treatment for intermediate-risk patients
  • TURBT and then some
  • References
  • About Mitomycin-C Kyowa
  • Mechanism of Action
  • Solubility
  • Stability
  • Dosage, indication & side effects
  • Useful links
  1. Top >
  2. for Healthcare Professionals >
  3. TURBT and then some

Treatment of non-muscle invasive bladder cancer

TURBT and then some

An immediate instillation of chemotherapy for low- or intermediate-risk patients following TURBT1

  • A core component of EAU recommendations for adjuvant treatment1
  • Proven to significantly reduce tumour recurrence vs. TURBT alone2
  • Treatment within 24 hours of surgery maximises effectiveness3

Repeat doses of Mitomycin-C are an effective, well-tolerated choice for your intermediate-risk patients4,5

  • No difference in survival time or progression rates between Mitomycin-C or BCG treatments5
  • Superior side-effect profile vs. BCG5